Publications

1 - 10 of 57 results

Search term:

The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-Oncology Vrije Universiteit Brussel KU Leuven Flanders Institute for Biotechnology

Isaure Vanmeerbeek, Jannes Govaerts, Raquel S Laureano, Jenny Sprooten, Stefan Naulaerts, Daniel M Borras, Damya Laoui, Massimiliano Mazzone, Jo Van Ginderachter, Abhishek D Garg, et al.

Tumour-associated macrophages (TAMs) are essential players in the tumour microenvironment (TME) and modulate various pro-tumorigenic functions such as immunosuppression, angiogenesis, cancer cell proliferation, invasion and metastasis, along with resistance to anti-cancer therapies. TAMs also mediate important anti-tumour functions and can clear dying cancer cells via efferocytosis. Thus, not surprisingly, TAMs exhibit heterogeneous ...

Landscape of KRAS(G12C), Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers KU Leuven

Eric Van Cutsem
PURPOSE: Promising single-agent activity from sotorasib and adagrasib in KRASG12C-mutant tumors has provided clinical evidence of effective KRAS signaling inhibition. However, comprehensive analysis of KRAS-variant prevalence, genomic alterations, and the relationship between KRAS and immuno-oncology biomarkers is lacking. MATERIALS AND METHODS: Retrospective analysis of deidentified records from 79,004 patients with various cancers who ...

Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors KU Leuven

Benoit Beuselinck
BACKGROUND: Immuno-oncology (IO) therapies have changed the treatment standards of metastatic renal cell carcinoma (mRCC). However, the effectiveness of targeted therapy following discontinuation of IO therapy in real-world settings has not been well studied. OBJECTIVE: To describe treatment sequence and assess clinical effectiveness of targeted therapy for mRCC patients who received prior IO therapy. DESIGN, SETTING, AND PARTICIPANTS: A ...

Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations for the management of triple-negative breast cancer University of Antwerp

Hesham Elghazaly, Hope S. Rugo, Hamdy A. Azim, Sandra M. Swain, Banu Arun, Matti Aapro, Edith A. Perez, Benjamin O. Anderson, Frederique Penault-Llorca, Pierfranco Conte, et al.
Simple Summary Despite the impressive progress in the treatment of triple-negative breast cancer (TNBC), oncologists still face several provocative clinical scenarios in daily practice where clear evidence-based recommendations are lacking, and expert opinion is of utmost importance. In an attempt to seek guidance for these controversial topics in TNBC management, a consensus recommendations session for TNBC was held during the 12th round of the ...

Targeting the CD73-adenosine axis in immuno-oncology University of Antwerp Vrije Universiteit Brussel

The ectonucleotidases CD39 and CD73 are cell surface enzymes that catabolize the breakdown of extracellular ATP into adenosine. As such, they constitute critical components of the extracellular purinergic pathway and play important roles in maintaining tissue and immune homeostasis. With the coming of age of cancer immunotherapy, ectonucleotidases and adenosine receptors have emerged as novel therapeutic targets to enhance antitumor immune ...

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinom KU Leuven Ghent University

Thomas Gevaert, Beppe Floris
Assessment of the immune response to tumors is growing in importance as the prognostic implications of this response are increasingly recognized, and as immunotherapies are evaluated and implemented in different tumor types. However, many different approaches can be used to assess and describe the immune response, which limits efforts at implementation as a routine clinical biomarker. In part 1 of this review, we have proposed a standardized ...

A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology. KU Leuven

Jenny Sprooten, An Coosemans, Abhishek Garg
Non-invasive, immuno-dynamic, biomarkers positioned in cancer patient's blood milieu with immuno-oncological applications are rare. We recently established a "first-in-class" serum functional immunodynamics status (sFIS) assay, wherein in vitro assessment of serum-induced myeloid NFkB and/or interferon (IFN) response-signaling can be performed to "mimic" in situ patient's serum immune-biology. This modality has clear implications for ...

Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study KU Leuven

Benoit Beuselinck
BACKGROUND: Limited data exist on the clinical effectiveness of second-line (2L) vascular endothelial growth factor (receptor) targeted inhibitor (VEGF(R)i) sunitinib after first-line (1L) immuno-oncology (IO) therapy for patients with metastatic renal cell carcinoma (mRCC) in real-world settings. METHODS: A retrospective cohort study among adult patients with mRCC treated with 2L sunitinib following 1L IO was conducted from select International ...